Antiretroviral therapy: Is it the right time for new strategies?

被引：2

作者：

Abrescia, N ^{[1
]}

D'Abbraccio, M ^{[1
]}

Busto, A ^{[1
]}

Maddaloni, A ^{[1
]}

Figoni, M ^{[1
]}

De Marco, M ^{[1
]}

机构：

[1] AO Cotugno Reg Hosp Infect Dis, Div Infect Dis 4, I-80131 Naples, Italy

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2005年 / 2卷 / 06期

关键词：

HIV; AIDS; HAART; HIV treatment new strategies;

D O I：

10.2174/1570180054771536

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The current antiretroviral regimens in the long run, can lead to poor adherence to treatment, to emergence of resistant viral strains and different adverse effects limiting benefits of HAART. A variety of novel treatment strategies have been proposed to help the long-term management of HAART. The principal innovative therapeutic strategies under investigation will be discussed: treatment simplification, once daily regimens, structured or response guided treatment interruptions and proactive antiretroviral switching.

引用

页码：470 / 474

页数：5

共 36 条

[1] Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial [J].

Ananworanich, J ;

Nuesch, R ;

Le Braz, M ;

Chetchotisakd, P ;

Vibhagool, A ;

Wicharuk, S ;

Ruxrungtham, K ;

Furrer, H ;

Cooper, D ;

Hirschel, B .

AIDS, 2003, 17 (15) :F33-F37

[2] Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients [J].

Bucher, HC ;

Kofler, A ;

Nüesch, R ;

Young, J ;

Battegay, M ;

Opravil, M .

AIDS, 2003, 17 (17) :2451-2459

[3] Adverse effects of antiretroviral therapy [J].

Carr, A ;

Cooper, DA .

LANCET, 2000, 356 (9239) :1423-1430

[4] Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA [J].

Clumeck, N ;

Goebel, F ;

Rozenbaum, W ;

Gerstoft, J ;

Staszewski, S ;

Montaner, J ;

Johnson, M ;

Gazzard, B ;

Stone, C ;

Athisegaran, R ;

Moore, S .

AIDS, 2001, 15 (12) :1517-1526

[5]

D'Amato RM, 1998, ANTIVIR THER, V3, P147

[6] Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].

Deeks, SG ;

Wrin, T ;

Liegler, T ;

Hoh, R ;

Hayden, M ;

Barbour, JD ;

Hellmann, NS ;

Petropoulos, CJ ;

McCune, JM ;

Hellerstein, MK ;

Grant, RM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480

[7] Once-a-day highly active antiretroviral therapy: A systematic review [J].

Ena, J ;

Pasquau, F .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) :1186-1190

[8] Twice-daily trizivir versus combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: A formulation-switch trial [J].

Fischl, MA ;

Burnside, AF ;

Farthing, CF ;

Thompson, MA ;

Bellos, NC ;

Williams, VC ;

Kauf, TL ;

Wannamaker, PG ;

Shaefer, MS .

PHARMACOTHERAPY, 2003, 23 (11) :1432-1440

[9] The ideal nucleoside/nucleotide backbone [J].

Gallant, JE .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 :S44-S51

[10] Atazanavir [J].

Goldsmith, DR ;

Perry, CM .

DRUGS, 2003, 63 (16) :1679-1693

← 1 2 3 4 →